Novavax Inc.’s shares surged after its COVID-19 vaccine won backing from a panel of U.S. public health advisers, a crucial step in providing officials with another tool against the virus as cases start to rise again.
The 12-member panel of outside experts convened by the Centers for Disease Control and Prevention voted unanimously to recommend the shots for adults. CDC Director Rochelle Walensky signed off on the advice from the Advisory Committee on Immunization Practices, which allows the shot to finally go into arms. The stock gained 12% at the close of New York trading Tuesday.
“If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated,” Walensky said in a statement.
